These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

380 related items for PubMed ID: 31728839

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Evaluating the In Vivo Specificity of [18F]UCB-H for the SV2A Protein, Compared with SV2B and SV2C in Rats Using microPET.
    Serrano ME, Becker G, Bahri MA, Seret A, Mestdagh N, Mercier J, Mievis F, Giacomelli F, Lemaire C, Salmon E, Luxen A, Plenevaux A.
    Molecules; 2019 May 01; 24(9):. PubMed ID: 31052478
    [Abstract] [Full Text] [Related]

  • 24. Assessing Synaptic Density in Alzheimer Disease With Synaptic Vesicle Glycoprotein 2A Positron Emission Tomographic Imaging.
    Chen MK, Mecca AP, Naganawa M, Finnema SJ, Toyonaga T, Lin SF, Najafzadeh S, Ropchan J, Lu Y, McDonald JW, Michalak HR, Nabulsi NB, Arnsten AFT, Huang Y, Carson RE, van Dyck CH.
    JAMA Neurol; 2018 Oct 01; 75(10):1215-1224. PubMed ID: 30014145
    [Abstract] [Full Text] [Related]

  • 25. [(11)C]UCB-A, a novel PET tracer for synaptic vesicle protein 2A.
    Estrada S, Lubberink M, Thibblin A, Sprycha M, Buchanan T, Mestdagh N, Kenda B, Mercier J, Provins L, Gillard M, Tytgat D, Antoni G.
    Nucl Med Biol; 2016 Jun 01; 43(6):325-32. PubMed ID: 27260773
    [Abstract] [Full Text] [Related]

  • 26. Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties.
    Gillard M, Fuks B, Leclercq K, Matagne A.
    Eur J Pharmacol; 2011 Aug 16; 664(1-3):36-44. PubMed ID: 21575627
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Good manufacturing procedure production of [18 F]SynVesT-1, a radioligand for in vivo positron emission tomography imaging of synaptic vesicle glycoprotein 2A.
    Dahl K, Larsson S, Bonn P, Wallin A, Itsenko O, Schöll M.
    J Labelled Comp Radiopharm; 2022 Oct 16; 65(12):315-322. PubMed ID: 36044030
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Validation of an (18)F-labeled biphenylalkyne as a positron emission tomography imaging agent for beta-amyloid plaques.
    Wey SP, Weng CC, Lin KJ, Yao CH, Yen TC, Kung HF, Skovronsky D, Kung MP.
    Nucl Med Biol; 2009 May 16; 36(4):411-7. PubMed ID: 19423009
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. PET imaging of synaptic density: A new tool for investigation of neuropsychiatric diseases.
    Cai Z, Li S, Matuskey D, Nabulsi N, Huang Y.
    Neurosci Lett; 2019 Jan 19; 691():44-50. PubMed ID: 30075287
    [Abstract] [Full Text] [Related]

  • 33. Kinetic evaluation and test-retest reproducibility of [11C]UCB-J, a novel radioligand for positron emission tomography imaging of synaptic vesicle glycoprotein 2A in humans.
    Finnema SJ, Nabulsi NB, Mercier J, Lin SF, Chen MK, Matuskey D, Gallezot JD, Henry S, Hannestad J, Huang Y, Carson RE.
    J Cereb Blood Flow Metab; 2018 Nov 19; 38(11):2041-2052. PubMed ID: 28792356
    [Abstract] [Full Text] [Related]

  • 34. Reduced synaptic vesicle protein 2A binding in temporal lobe epilepsy: A [11 C]UCB-J positron emission tomography study.
    Finnema SJ, Toyonaga T, Detyniecki K, Chen MK, Dias M, Wang Q, Lin SF, Naganawa M, Gallezot JD, Lu Y, Nabulsi NB, Huang Y, Spencer DD, Carson RE.
    Epilepsia; 2020 Oct 19; 61(10):2183-2193. PubMed ID: 32944949
    [Abstract] [Full Text] [Related]

  • 35. Enabling Efficient Positron Emission Tomography (PET) Imaging of Synaptic Vesicle Glycoprotein 2A (SV2A) with a Robust and One-Step Radiosynthesis of a Highly Potent 18F-Labeled Ligand ([18F]UCB-H).
    Warnier C, Lemaire C, Becker G, Zaragoza G, Giacomelli F, Aerts J, Otabashi M, Bahri MA, Mercier J, Plenevaux A, Luxen A.
    J Med Chem; 2016 Oct 13; 59(19):8955-8966. PubMed ID: 27598384
    [Abstract] [Full Text] [Related]

  • 36. Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action.
    Nicolas JM, Hannestad J, Holden D, Kervyn S, Nabulsi N, Tytgat D, Huang Y, Chanteux H, Staelens L, Matagne A, Mathy FX, Mercier J, Stockis A, Carson RE, Klitgaard H.
    Epilepsia; 2016 Feb 13; 57(2):201-9. PubMed ID: 26663401
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Validation and noninvasive kinetic modeling of [11C]UCB-J PET imaging in mice.
    Bertoglio D, Verhaeghe J, Miranda A, Kertesz I, Cybulska K, Korat Š, Wyffels L, Stroobants S, Mrzljak L, Dominguez C, Liu L, Skinbjerg M, Munoz-Sanjuan I, Staelens S.
    J Cereb Blood Flow Metab; 2020 Jun 13; 40(6):1351-1362. PubMed ID: 31307287
    [Abstract] [Full Text] [Related]

  • 40. SV2A PET Imaging Is a Noninvasive Marker for the Detection of Spinal Damage in Experimental Models of Spinal Cord Injury.
    Bertoglio D, Halloin N, Lombaerde S, Jankovski A, Verhaeghe J, Nicaise C, Staelens S.
    J Nucl Med; 2022 Aug 13; 63(8):1245-1251. PubMed ID: 35027368
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.